NADPH Oxidase: A Potential Therapeutic Target to Reduce Primary Sclerosis Cholangitis Following Liver Transplantation

The molecular mechanisms and causes of primary sclerosis cholangitis (PSC) post-liver transplantation are still unclear. PSC is a progressive cholestatic hepatobiliary disease that happens in about 25% of patients post-liver transplantation and requires re-- transplantation. Nicotinamide adenine din...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Current medicinal chemistry Ročník 32; číslo 32; s. 8598
Hlavní autoři:	Aliakbarian, Mohsen, Ashrafzadeh, Kiarash, Ferns, Gordon A, Hadian, Reyhaneh, Khodashahi, Rozita, Arjmand, Mohammad-Hassan
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	United Arab Emirates 01.01.2025
Témata:	Animals Cholangitis, Sclerosing - drug therapy Cholangitis, Sclerosing - enzymology Cholangitis, Sclerosing - etiology Cholangitis, Sclerosing - metabolism Cholangitis, Sclerosing - prevention & control Humans Liver Transplantation - adverse effects NADPH Oxidases - antagonists & inhibitors NADPH Oxidases - metabolism Reactive Oxygen Species - metabolism fibrosis primary sclerosis cholangitis ischemic reperfusion injury NADPH oxidase liver transplantation
ISSN:	1875-533X, 1875-533X
On-line přístup:	Zjistit podrobnosti o přístupu
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!